首页> 外文期刊>Annals of Internal Medicine >Erratum: Rilonacept for colchicine-resistant or -intolerant familial mediterranean fever ((Annals of Internal Medicine (2012) 157 533-541))
【24h】

Erratum: Rilonacept for colchicine-resistant or -intolerant familial mediterranean fever ((Annals of Internal Medicine (2012) 157 533-541))

机译:勘误:耐秋水仙碱或不耐受家族性地中海热的Rilonacept((Annals of Internal Medicine(2012)157 533-541))

获取原文
获取原文并翻译 | 示例
           

摘要

A recent article (1) had several errors in the results that were caused by errors in the published WinBUGS code. Page 533, Results section of abstract, left column, last 3 lines: ". . . the rilonacept-placebo attack risk ratio was 0.45 [not 0.59] (SD, 0.13 [not 0.12]) (equal-tail 95% credible interval, 0.26 [not 0.39] to 0.77 [not 0.85])." Page 535, right column, Statistical Analysis section, 3rd paragraph, lines 5 to 9: "We developed models based on noninfor-mative (log-normal distribution mean, 0 [SD, 10]), enthusiastic (mean, ln(0.5) [not 0.5] [SD, 0.125]), and skeptical (mean, 0 [SD, 0.125]) priors for the attack rate risk ratio (RR) (rilonacept-placebo)."
机译:最近的文章(1)中有一些错误,这些错误是由已发布的WinBUGS代码中的错误引起的。第533页,摘要的结果部分,左栏,最后3行:“……rilonacept-安慰剂的发作风险比是0.45 [不是0.59](SD,0.13 [不是0.12])(等尾95%可信区间, 0.26 [not 0.39] to 0.77 [not 0.85])。”页面535,右列,统计分析部分,第3段,第5至9行:“我们基于非信息性(对数正态分布均值,0 [SD,10]),热情(均值,ln(0.5))开发了模型[不是0.5] [SD,0.125]),并且对攻击率风险比(RR)(rilonacept-安慰剂)持怀疑态度(平均值,0 [SD,0.125])。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号